These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26012156)

  • 41. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation.
    Cantarovich D; Karam G; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Le Normand L; Soulillou JP
    Kidney Int; 1998 Oct; 54(4):1351-6. PubMed ID: 9767555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of generic cyclosporine arpimune in Filipino low-risk primary kidney transplant recipients.
    Pamugas GE; Danguilan RA; Lamban AB; Mangati VB; Ona ET
    Transplant Proc; 2012 Jan; 44(1):101-8. PubMed ID: 22310590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
    Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
    Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction.
    Cantarovich D; Rostaing L; Kamar N; Saint-Hillier Y; Ducloux D; Mourad G; Garrigue V; Wolf P; Ellero B; Cassuto E; Albano L; Soulillou JP;
    Transpl Int; 2010 Mar; 23(3):313-24. PubMed ID: 19843296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.
    Rinaldi M; Pellegrini C; Martinelli L; Goggi C; Gavazzi A; Campana C; Arbustini E; Grossi P; Regazzi M; Ippoliti G; Vigano M
    J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation.
    Barone GW; Ketel BL; Abul-Ezz SR; Lightfoot ML
    JOP; 2002 Mar; 3(2):49-53. PubMed ID: 11884766
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The mechanisms of chronic kidney damage in renal transplant and their possible reversibility].
    Schena FP; Maiorano A; Rossini M
    G Ital Nefrol; 2008; 25 Suppl 44():S11-4. PubMed ID: 19048580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
    Thierry A; Le Meur Y; Ecotière L; Abou-Ayache R; Etienne I; Laurent C; Vuiblet V; Colosio C; Bouvier N; Aldigier JC; Rerolle JP; Javaugue V; Gand E; Bridoux F; Essig M; Hurault de Ligny B; Touchard G
    Transpl Int; 2016 Jan; 29(1):23-33. PubMed ID: 26729582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: long-term follow-up and study of metabolic consequences.
    Sobh MA; Hamdy AF; El Agroudy AE; El Sayed K; El-Diasty T; Bakr MA; Ghoneim MA
    Am J Kidney Dis; 2001 Mar; 37(3):510-7. PubMed ID: 11228175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of calcineurin inhibitor nephrotoxicity in renal transplantation.
    Jacquet A; Francois H; Frangie C; Ahmad L; Charpentier B; Durrbach A
    Transpl Immunol; 2008 Nov; 20(1-2):29-31. PubMed ID: 18817870
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients.
    Hermann M; Asberg A; Christensen H; Reubsaet JL; Holdaas H; Hartmann A
    Eur J Clin Pharmacol; 2005 Mar; 61(1):59-62. PubMed ID: 15711834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
    Zhang Y; Zhang XD; Wang Y
    Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complete reversal of FK 506 induced diabetes in a liver transplant recipient by change of immunosuppression to cyclosporine A.
    Kanzler S; Lohse AW; Schirmacher P; Hermann E; Otto G; Meyer zum Büschenfelde KH
    Z Gastroenterol; 1996 Feb; 34(2):128-31. PubMed ID: 8659188
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation.
    Tanaka Y; Hasegawa T; Chen Z; Okita Y; Okada K
    J Thorac Cardiovasc Surg; 2009 Sep; 138(3):744-51. PubMed ID: 19698865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Preventing rejection, minimizing toxicity: optimized therapy with cyclosporin].
    MMW Fortschr Med; 2002 Jan; 144(3-4):59. PubMed ID: 11862796
    [No Abstract]   [Full Text] [Related]  

  • 59. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
    Tsai SF; Cheng CY; Shu KH; Wu MJ
    Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.